|
|
 Previous Article | Table of Contents | Next Article 
Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)
Maria R. Baer,
Carleton C. Stewart,
David Lawrence,
Diane C. Arthur,
John C. Byrd,
Frederick R. Davey,
Charles A. Schiffer, and
Clara D. Bloomfield
From Roswell Park Cancer Institute, Buffalo, NY; University of Minnesota, Minneapolis, MN; Walter Reed Army Medical Center, Washington, DC; SUNY Health Science Center at Syracuse, Syracuse, NY; and University of Maryland Cancer Center, Baltimore, MD.
Although acute myeloid leukemia (AML) with t(8; 21) (q22; q22) is associated with a high complete remission (CR) rate and prolonged disease-free survival, treatment outcome is not universally favorable. Identifying factors that predict for treatment outcome might allow therapy to be optimized based on risk. AML with t(8; 21) has a distinctive immunophenotype, characterized by expression of the myeloid and stem cell antigens CD13, CD15, CD34, and HLADr, and frequent expression of the B-cell antigen CD19 and the neural cell adhesion molecule CD56, a natural killer cell/stem cell antigen. Because CD56 expression has been associated with both extramedullary leukemia and multidrug resistance, we sought to correlate CD56 expression with treatment outcome in AML with t(8; 21). Pretreatment leukemia cells from 29 adult de novo AML patients with t(8; 21) treated on Cancer and Leukemia Group B (CALGB) protocols were immunophenotyped by multiparameter flow cytometry as part of a prospective immunophenotyping study of adult AML (CALGB 8361). CD56 was expressed in 16 cases (55%). There was no correlation between CD56 expression and age, sex, white blood cell count, granulocyte count, the presence of additional cytogenetic abnormalities, or the presence of extramedullary disease at diagnosis. The CR rate to standard-dose cytarabine and daunorubicin was similar for cases with and without CD56 expression (88% v 92%; P = 1.0). Post-CR therapy included at least one course of high-dose cytarabine in 24 of 26 patients who achieved CR; numbers of courses administered were similar in cases with and without CD56 expression. Although post-CR therapy did not differ, CR duration was significantly shorter in cases with CD56 expression compared with those without (median, 8.7 months v not reached; P = .01), as was survival (median, 16.5 months v not reached; P = .008). We conclude that CD56 expression in AML with t(8; 21) is associated with significantly shorter CR duration and survival. Our results suggest that CD56 expression may be useful in stratifying therapy for this subtype of AML.
Blood, Vol. 90 No. 4 (August 15), 1997:
pp. 1643-1648
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Fischer, N. Gokbuget, S. Schwartz, T. Burmeister, H. Rieder, M. Bruggemann, D. Hoelzer, and E. Thiel
CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy
Haematologica,
February 1, 2009;
94(2):
224 - 229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. King and J. M. Rowe
Recent Developments in Acute Myelogenous Leukemia Therapy
Oncologist,
October 1, 2007;
12(suppl_2):
14 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gattenloehner, S. Chuvpilo, C. Langebrake, D. Reinhardt, H.-K. Muller-Hermelink, E. Serfling, A. Vincent, and A. Marx
Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression
Blood,
September 15, 2007;
110(6):
2027 - 2033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Assaf, S. Gellrich, S. Whittaker, A. Robson, L. Cerroni, C. Massone, H. Kerl, C. Rose, A. Chott, S. Chimenti, et al.
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer
J. Clin. Pathol.,
September 1, 2007;
60(9):
981 - 989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Cairoli, A. Beghini, G. Grillo, G. Nadali, F. Elice, C. B. Ripamonti, P. Colapietro, M. Nichelatti, L. Pezzetti, M. Lunghi, et al.
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
Blood,
May 1, 2006;
107(9):
3463 - 3468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Shimada, T. Taki, K. Tabuchi, A. Tawa, K. Horibe, M. Tsuchida, R. Hanada, I. Tsukimoto, and Y. Hayashi
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group
Blood,
March 1, 2006;
107(5):
1806 - 1809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lengerke, S. Wirths, L. Kanz, H. Hebart, E. Kaiserling, S. M. Krober, M. S. Horger, and K. Soennichsen
Unusual Leukemia Presentations: CASE 1. Pulmonary Chloroma Preceded by Leukemia Cutis 7 Years Earlier
J. Clin. Oncol.,
August 20, 2005;
23(24):
5837 - 5839.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.F. Schlenk, A. Benner, J. Krauter, T. Buchner, C. Sauerland, G. Ehninger, M. Schaich, B. Mohr, D. Niederwieser, R. Krahl, et al.
Individual Patient Data-Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup
J. Clin. Oncol.,
September 15, 2004;
22(18):
3741 - 3750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Saussoy, J.-L. Vaerman, N. Straetmans, V. Deneys, G. Cornu, A. Ferrant, and D. Latinne
Differentiation of Acute Myeloid Leukemia from B- and T-Lineage Acute Lymphoid Leukemias by Real-Time Quantitative Reverse Transcription-PCR of Lineage Marker mRNAs
Clin. Chem.,
July 1, 2004;
50(7):
1165 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Krauter, K. Gorlich, O. Ottmann, M. Lubbert, H. Dohner, W. Heit, L. Kanz, A. Ganser, and G. Heil
Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor Leukemias
J. Clin. Oncol.,
December 1, 2003;
21(23):
4413 - 4422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, J. W. Andersen, C. A. Schiffer, F. R. Appelbaum, J. H. Feusner, W. G. Woods, A. Ogden, H. Weinstein, L. Shepherd, C. Willman, et al.
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
Blood,
December 15, 2002;
100(13):
4298 - 4302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nguyen, T. Leblanc, P. Fenaux, F. Witz, D. Blaise, A. Pigneux, X. Thomas, F. Rigal-Huguet, B. Lioure, A. Auvrignon, et al.
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup
Blood,
May 15, 2002;
99(10):
3517 - 3523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone, D. T. Berg, S. L. George, R. K. Dodge, P. A. Paciucci, P. P. Schulman, E. J. Lee, J. O. Moore, B. L. Powell, M. R. Baer, et al.
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
Blood,
August 1, 2001;
98(3):
548 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Baer, C. C. Stewart, R. K. Dodge, G. Leget, N. Sule, K. Mrozek, C. A. Schiffer, B. L. Powell, J. E. Kolitz, J. O. Moore, et al.
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
Blood,
June 1, 2001;
97(11):
3574 - 3580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al.
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
Blood,
November 1, 2000;
96(9):
2993 - 3000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ferrara, F. Morabito, B. Martino, G. Specchia, V. Liso, F. Nobile, P. Boccuni, R. Di Noto, F. Pane, M. Annunziata, et al.
CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy
J. Clin. Oncol.,
March 13, 2000;
18(6):
1295 - 1300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, J. M. Cayuela, S. Martini, A. Baruchel, P. Rousselot, G. Socie, P. Berthou, J. P. Jouet, N. Straetmans, F. Sigaux, et al.
Evaluation of Minimal Residual Disease Using Reverse-Transcription Polymerase Chain Reaction in t(8;21) Acute Myeloid Leukemia: A Multicenter Study of 51 Patients
J. Clin. Oncol.,
February 14, 2000;
18(4):
788 - 788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, R. K. Dodge, A. Carroll, M. R. Baer, C. Edwards, J. Stamberg, M. Qumsiyeh, J. O. Moore, R. J. Mayer, F. Davey, et al.
Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered
J. Clin. Oncol.,
December 1, 1999;
17(12):
3767 - 3775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. K. Murray, E. Estey, E. Paietta, R. S. Howard, W. J. Edenfield, S. Pierce, K. P. Mann, C. Bolan, and J. C. Byrd
CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome?
J. Clin. Oncol.,
January 1, 1999;
17(1):
293 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
